These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 26523836)

  • 21. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
    Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease.
    Mirre E; Brousse V; Berteloot L; Lambot-Juhan K; Verlhac S; Boulat C; Dumont MD; Lenoir G; de Montalembert M
    Eur J Haematol; 2010 Mar; 84(3):259-65. PubMed ID: 19912310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
    Ware RE; Schultz WH; Yovetich N; Mortier NA; Alvarez O; Hilliard L; Iyer RV; Miller ST; Rogers ZR; Scott JP; Waclawiw M; Helms RW
    Pediatr Blood Cancer; 2011 Dec; 57(6):1011-7. PubMed ID: 21826782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac iron overload in sickle-cell disease.
    Meloni A; Puliyel M; Pepe A; Berdoukas V; Coates TD; Wood JC
    Am J Hematol; 2014 Jul; 89(7):678-83. PubMed ID: 24664847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.
    Helton KJ; Adams RJ; Kesler KL; Lockhart A; Aygun B; Driscoll C; Heeney MM; Jackson SM; Krishnamurti L; Miller ST; Sarnaik SA; Schultz WH; Ware RE;
    Blood; 2014 Aug; 124(6):891-8. PubMed ID: 24914136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
    Brown K; Subramony C; May W; Megason G; Liu H; Bishop P; Walker T; Nowicki MJ
    J Pediatr Hematol Oncol; 2009 May; 31(5):309-12. PubMed ID: 19415007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels.
    Karam LB; Disco D; Jackson SM; Lewin D; McKie V; Baker RD; Baker SS; Laver JH; Nietert PJ; Abboud MR
    Pediatr Blood Cancer; 2008 Jan; 50(1):62-5. PubMed ID: 17457853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sickle cell anaemia: current therapies.
    Vermylen C
    Transfus Apher Sci; 2013 Oct; 49(2):151-4. PubMed ID: 23954416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
    Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
    Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of iron overload on oxidative stress in sickle cell anemia.
    Dos Santos TE; de Sousa GF; Barbosa MC; Gonçalves RP
    Biomark Med; 2012 Dec; 6(6):813-9. PubMed ID: 23227847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
    Ware RE; Helms RW;
    Blood; 2012 Apr; 119(17):3925-32. PubMed ID: 22318199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
    Suliman H; Wali Y; Al Saadoon M; Zechariah M; William RR; Gujjar A; Pathare A
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):42-4. PubMed ID: 19125086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.
    Hankins JS; Smeltzer MP; McCarville MB; Aygun B; Hillenbrand CM; Ware RE; Onciu M
    Eur J Haematol; 2010 Jul; 85(1):51-7. PubMed ID: 20374273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.
    Manganas K; Delicou S; Xydaki A; Koskinas J
    Hemoglobin; 2022 Mar; 46(2):114-117. PubMed ID: 36069257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of cardiac iron deposition in sickle cell disease using 3.0 Tesla cardiovascular magnetic resonance.
    Ibrahim el-SH; Rana FN; Johnson KR; White RD
    Hemoglobin; 2012; 36(4):343-61. PubMed ID: 22563880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of iron overload in sickle cell disease.
    Olivieri NF
    Semin Hematol; 2001 Jan; 38(1 Suppl 1):57-62. PubMed ID: 11206962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
    Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.